A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/55 (2006.01) A61K 31/35 (2006.01) A61K 31/352 (2006.01) A61K 31/353 (2006.01) A61K 31/38 (2006.01) A61K 31/382 (2006.01) A61K 31/445 (2006.01) A61K 31/4453 (2006.01) A61K 31/453 (2006.01) A61K 31/4725 (2006.01) A61K 31/565 (2006.01)
Patent
CA 2163158
The present invention provides methods for inhibiting bone loss comprising administering to a mammal in need of treatment a bone loss inhibiting amount of a compound of formula I or formula II Image I wherein R1 is -H or is a bivalent moiety which distances L from the B-ring by 6-8 intervening atoms; R2 is -H or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted cycloalkyl group having 5-7 carbon atoms, a bivalent moiety which joins R3 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing; R3 is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted bivalent moiety which joins R2 and L to form a 5- to 7- membered heterocyclic ring, and halo-substituted derivatives of the foregoing; R4 is hydrogen or lower alkyl; R5 and R6 each are independently hydrogen, hydroxy, or a moiety which is converted to hydroxy in vivo; L is -CON< or -N<; and the dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof; and Image II wherein Q is a moiety having the formula Image ; or ? R1 ? B ? R7 ? L ? G ; R1 is absent or is a bivalent moiety which distances L from the B-ring by 6-8 intervening atoms; R2 is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted cycloalkyl group having 5-7 carbon atoms, a bivalent moiety which joins R3 and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing; R3 is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted bivalent moiety which joins R2 and L to form a 5- to 7- membered heterocyclic ring, and halo-substituted derivatives of the foregoing; L is -CON< or -N<; B is -O-, -S-, -CH2-phenyl-O-, -phenyl-O-, or -benzyl -O -; R7 is absent or selected from the group consisting of straight- or branched-chain alkylene, straight- or branched-chain alkenylene, phenylene, and fluoro-substituted analogs of the foregoing; G is a moiety which together with L forms a substituted or unsubstituted heterocyclic ring having at least one nitrogen atom or is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (C3-C7)cycloalkyl, halo(lower)alkyl, cyano(lower)alkyl, carboxy(lower)alkyl, (lower)alkoxycarbonyl(lower)alkyl, (C6-C10)aryl, (C7-C11)aryl akyl, di(lower)alkylamino(lower)alkyl, and fluoro-substituted analogs of the foregoing; R4 is hydrogen or lower alkyl; R5 and R6 each are independently hydrogen, hydroxy, or a moiety which is converted to hydroxy in vivo; Z is -O-, -S-, -CH2-, -NH-; or -N(CH3)-; and the dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof.
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Methods for inhibiting bone loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting bone loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting bone loss will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1895009